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Cystic fibrosis (CF) patients suffer typically from bacterial infections of their airways. Whilst current antibiotic-based treatment of these
infections has brought much benefit to patients, it has been difficult to make either direct or indirect assessments of the in vivo efficacy of any
specific treatment used. Traditional culture-based assessment has for example been rarely used to determine the direct impact of therapy on the
bacteria in the airways. Instead, the “success” of a treatment is most often gauged through measures of respiratory and general health. New culture-
independent approaches though are emerging that offer much promise here however in allowing a more comprehensive evaluation of
antimicrobial efficacy. These new methods offer an opportunity to examine bacterial outcomes rather than host outcomes alone. Application of
these novel techniques in a systematic way will lead to the rationalisation and, likely greater still individualisation, of therapy for CF patients. This
review discusses host and microbiological factors that may influence antibiotic efficacy. Moreover, the degree to which the inherent complexity of
CF respiratory infections complicates the process of determining treatment impact and the need to identify more robust microbiological outcome
measures will also be reviewed.
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Despite much progress, bacterial airway infections still
dictate the course of respiratory disease in patients with cystic
fibrosis (CF). The high prevalence of bacterial airway infections
in CF patients is linked to mutations in an epithelial chloride
channel, the CF transmembrane conductance regulator (CFTR),
that result in a number of defects in innate immunity and airway
clearance [1]. Antibiotic treatment of these infections remains a
cornerstone of therapy, with improvements in this field
considered to be a major factor in the increased life expectancy
that has been achieved over recent decades [2–5]. Since chronic
lung disease is the main determinant of morbidity and mortality
in CF [6–8], and infections are thought to be a key driver of CF
lung disease [9,10], the issues surrounding antibiotic usage have
important implications for the prognosis of these patients.
Pseudomonas aeruginosa is the dominant infecting organism
in the majority of adult CF patients [11], and as such, is the
principal target of antibiotic therapy. However, many bacteria
other than P. aeruginosa are frequently cultured from the
respiratory secretions of CF patients, both in the absence of
P. aeruginosa and co-infecting with this pathogen, with antibiotic
treatment also routinely chosen to target these bacteria. These
pathogens include methicillin-susceptible Staphylococcus aureus
(MSSA), methicillin-resistant S. aureus (MRSA), members of the
Burkholderia cepacia complex (particularly B. cenocepacia,
B. dolosa and B. multivorans), Haemophilus influenzae,
Stenotrophomonas maltophilia, Achromobacter (formerly Alca-
ligenes) xylosoxidans, and non-tuberculousmycobacteria (NTM)
species (in particular M. avium-intracellulare complex,
M. chelonae, and M. abscessus) [5]. In a substantial proportion
of children with CF treated for respiratory exacerbations, none of
these “standard pathogens” are cultured, necessitating the
selection of antibiotics based on clinician experience or patient
history [12]. Furthermore, antibiotic treatment approaches often
differ between different centres and countries [13], complicating
the interpretation of how “current strategies” are faring, and
giving rise to a great diversity of antimicrobial strategies in current
use. The application of culture-independent analysis has revealed
the common presence of a yet much wider group of species in the
lower respiratory tract of CF patients [14–24]. However, whilst
the clinical significance of these additional species remains to be
determined, they are usually not addressed by antibiotic treatment
strategies.
Choices regarding antibiotic strategies in CF, including drug
selection and delivery method, have traditionally been shaped
by a number of integrated factors, including toxicological,
pharmacokinetic, and pharmacodynamic considerations, as wellas cost; also considered are in vitro susceptibility test
parameters, patients' clinical status, patient allergies, and past
success rate of intervention, as determined by endpoints such as
lung function, symptoms, or time to next infective exacerbation.
Each of these issues is important in the decision to choose a
particular antimicrobial strategy; however, the in vivo interac-
tion between host, microbe and antibiotic that is fundamental to
therapeutic efficacy is difficult to predict. Current protocols
rarely use culture-based data to evaluate the bacterial impact of
treatment; success is most often gauged by subjective and
objective measures of respiratory health, such as an increase in
lung function or the resolution of cough severity, which are
practical yet indirect measures of antibiotic efficacy [25].
The CF airway represents a complex system, where microbial
populations, host defences, and antimicrobial therapy all interact
in an altered physiochemical environment that results from the
underlying genetic defect but is influenced by a range of wider
factors. The reasons that these interacting factors result in severe
disease in some CF patients, and more mild disease in others, are
not fully understood. Nor is it clear why some patients experience
periods of relatively stable pulmonary status, punctuated by
periods of acute exacerbations of respiratory symptoms, or why
the frequency of these periods differs between individuals. When
dealing with such an interacting system, it becomes very difficult
to accurately assess the impact of a therapy aimed at any one
component, particularly when the relationship between that
component and the final outcome measure is poorly understood
(as is often the case in CF microbiology).
The need for better insight into the effects of antimicrobial
drugs within the infected airways of CF patients is illustrated by
the fact that antibiotic treatment of these chronic bacterial lung
infections has seldom resulted in the eradication of the
microbial pathogens being targeted (usually P. aeruginosa in
clinical studies, [26]), but rather achieved only a reduction in the
bacterial load in the patients' airways [27,28]. Because most
current, general concepts driving antibiotic treatment are based
on observations from acute infections for which antibiotics are
usually curative, including pneumonia and sepsis, this relatively
tepid response to antibiotic therapy is often found to be
surprising. The additional observation that antibiotics can
eradicate P. aeruginosa infections when initiated early after
initial detection, but not later, is equally confusing, since the
differences between these two infectious states are not well
defined. Moreover, the impact of antibiotic therapy on bacteria
not routinely targeted or even cultured (the “bystanders”) are
not well understood. Therefore, many issues remain to be
clarified regarding the microbial determinants of CF lung
disease and of response to antibiotics.
Box 1
Current antibiotic therapy in chronically colonised adult CF patients.
Current antibiotic therapy in chronically infected adult CF patients
The severity and aetiology of lower airway infections can differ
greatly between CF patients [9]. As such, therapies used also vary
considerably. Below, however, is a broad overview oftypical
antibiotic therapies in adult CF patients.
Maintenance therapy
Inhaled antibioticsare oftenusedduring periods of quiescence inan
attempt topreserve lungfunction and reduceneed for IV antibiotics
to control infection. Such maintenance therapy is recommended
for patients with chronic P. aeruginosa infection [147]. The
majority of patients receive twice daily colistin or tobramycin by
inhalation (tobramycin given in one month on/one month off
regimen) [5]. Courses of IV antibiotics may also be given as part of
maintenance therapy.
Treatment of acute exacerbation of pulmonary symptoms
Patients chronically colonised by P. aeruginosa typically receive
two IVanti-pseudomonal antibioticswith differentmodesof action
to reduce the development of resistance and to provide potential
for synergy [5,42,181]. Standard treatment involves 10–14 day
courses, however, there is no rationale to support this. In patients
colonisedbyamember of theB.cepaciacomplex, thehigh levelsof
resistance seen to many anti-pseudomonals [42] must be
considered. There is currently no consensus on antibiotic
susceptibility testing as a basis for selection of IV antibiotics.
Whilst clinical experience indicate patients benefit from such
therapy, the evidence base for it remains poor.
Where patients are chronically infected with MSSA or
H. influenzae, treatment of exacerbations is typically by orally
administered antibiotics. Even in the absence of positive airway
culture, a 2 to 4 week course of oral antibiotics may be given in
response to any increase in respiratory symptoms where a viral
cold is suspected [5]. In such cases, antibiotics are typically
selected to coverMSSAandH. influenzae [5].There is no evidence
base for this practice.
Multi-resistant isolates
P. aeruginosa and innately resistant organisms such as Steno-
trophomonas maltophilia, Achromobacter (Alcaligenes) xylosox-
idans, Methicillin-resistant Staphylococcus aureus (MRSA), and
non-tuberculous mycobacteria are increasingly reported in CF
airway infections [182]. The optimal treatment for these resistant
bacteria, or even if treatment is always necessary, is not known.
All may be associated with either a symptomatic infection, or
respiratory exacerbation.
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available that provide sufficiently detailed data about the
complex microbiota in the CF lung, potentially affording a more
comprehensive evaluation of antimicrobial efficacy. These new
methods offer an opportunity to fundamentally re-examine and
rationalise CF antimicrobial therapy using microbial outcomes,
providing the means to develop a systematic basis for the
individualisation of therapy for CF patients [29]. However,
because the clinical significance and utility of these novel data
are yet to be determined, they are usually not used to choose and
monitor conventional antibiotic treatments.
Here we will consider these complex issues and provide new
directions for the future study of unresolved questions. We will
discuss host and microbiological factors that likely influence
antibiotic efficacy in this context. Further, the degree to which
the complexity of CF respiratory infections complicates the
process of determining treatment impact and the need to identify
more appropriate microbiological outcome measures will be
examined. Through this discussion, a rationale for the design of
more effective antibiotic strategies against chronic bacterial
respiratory infections in CF patients will be set out.
2. Early infection
Staphylococcus aureus and Haemophilus influenzae are the
bacterial species most commonly isolated from children with CF,
with P. aeruginosa being detected less frequently. The
relationship between P. aeruginosa and CF lung disease has
been well-studied, and a wealth of epidemiological evidence
supports an association of P. aeruginosa with worse outcomes
[30–32]. By comparison, the roles of S. aureus,H. influenzae, and
other species often culturable from the airways of children with
CF are less well-defined. However, anecdotal and epidemiolog-
ical evidence indicates that bacteria other than P. aeruginosamay
be important factors in both CF lung disease and response to
antibiotic therapy [27,28,33–36]. To further confuse matters, it is
clear that children can have lung disease and exacerbations even
in the absence of culture detection of these “CF related bacteria”
[12]. These observations have led to a lack of a standardised
approach to early CF infections.With respect toP. aeruginosa, as
discussed above, early antibiotic treatment for P. aeruginosa
culture-positivity can be effective for eradication of this pathogen
[37–44]. It has been reported that in the CF center in Copenhagen,
Denmark, there are virtually no children with CF below the age of
16 years who are chronically infected with P. aeruginosa (Tanja
Pressler, personal communication). Interestingly, the choice of
the antibiotic to be administered for early eradication does not
seem to be important. For instance, aerosolized colistin and oral
ciprofloxacin [38,43] or aerosolized tobramycin either alone
[39,41,42] or with ciprofloxacin [45] reveal similar success rates.
The determination of serum antibody titres against P. aeruginosa
[41,43,46]; and genotyping of P. aeruginosa [40,43] have
provided independent evidence of successful eradication of the
pathogen.
Data from various studies suggest that the window of
opportunity to eradicate P. aeruginosa from CF airways may be
around 12 weeks from initial detection [47–49]. The fact thatintravenously or inhaled and orally administered antibiotics are
effective in early eradication suggests that the CF-specific host
immune or clearance defects alone are not severe enough to
preclude later eradication of established P. aeruginosa infection.
Suggested explanations that remain for the decreasing response to
antibiotics include a gradual rise in P. aeruginosa densities in
airways, and a transition from planktonic cells in early infection to
biofilm-dwelling cells later [50], as well as the emergence of other
phenotypic adaptations that may decrease the response to
antibiotics [51].3. Chronic infection
Whilst treatment during early stages of disease focuses on
prevention of airway infection and eradication of bacterial
pathogens where detected, treatment during later infection
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of symptoms, usually without the expectation of eradication.
Although the considerations required for effective treatment of
these stages of infection differ, it can be argued that early
disease more closely resembles the surveillance and manage-
ment of acute infections found in other contexts. By contrast,
such approaches are less appropriate in the management of
chronic infections, such as those that typify adult CF respiratory
disease. The key components in the management of chronic
infection are maintenance therapy, designed to preserve lung
function and decrease the need for additional therapy, and the
treatment for acute respiratory exacerbations, designed to
alleviate acute symptoms and regain levels of lung function
that existed prior to exacerbation. In addition to these types of
therapy, prophylactic strategies may also be used at times of
increased risk of worsening, such as where viral respiratory
infections are suspected. These strategies are summarised in
Box 1.
Until today, no antibiotic therapy strategy has been
successful for the routine eradication of P. aeruginosa from
the airways of CF patients once the infection has become
chronic (commonly defined as repeated positive microbiolog-
ical cultures, e.g., three out of four cultures per year, and/or the
presence of positive serum antibodies against the pathogen
[52]). Multiple factors, determined by drug, bacterial, and host
characteristics, could impair the efficacy of antimicrobial drugs
in the chronically infected CF lung, forming the subject of
several reviews [53–55] (summarised in Fig. 1).
3.1. Physical barriers for antibiotics
During chronic P. aeruginosa infection, individual bacterial
cells are believed to commonly form large aggregates, usually
referred to as biofilms. Growth in biofilms, or biofilm-like
structures, may play a substantial role in the ability of bacteria to
resist eradication both by the host immune response and
antimicrobial therapy. In vivo data suggest that the exopoly-
saccharide matrix in which P. aeruginosa cells are embedded
can scavenge host innate immune molecules such as hypochlo-
rite, reduce polymorphonuclear cell chemotaxis, inhibit activa-
tion of complement, and decrease phagocytosis by neutrophils,Fig. 1. Bacterial factors influencing antibimacrophages and leukocytes [56–61]. Further, bacterial cells in
in vitro biofilm models are able to withstand substantially
higher concentrations of many antibiotics, with up to 100–
1000-fold higher levels often required to inhibit the growth or
kill biofilm-growing bacteria compared with planktonic bacteria
[62–64].
The chemical composition of CF airway secretions (in which
infection is most often localised) can also diminish antibiotic
efficacy. For example, in vitro “cidal” activity of aminoglyco-
sides has been shown to be completely inhibited in the presence
of sputum, permitting bacterial growth even when the antibiotic
concentration is ten times the minimum inhibitory concentration
[65], a phenomenon believed to be due to the binding of
aminoglycoside molecules to mucins and DNA [66]. However,
repeated dosing of antibiotics during therapy may saturate
binding sites [54,66], allowing therapeutic concentrations to be
achieved.
Physiochemical characteristics of CF airway secretions may
also prevent effective antibiotic function. For example, there is a
significant decrease in oxygen tensions within mucus plugs in
CF airways [67] and even in deeper layers of bacterial biofilms
themselves (Costerton et al., 1995), with a likely reduction in
the antimicrobial activity of many antibiotics [68–74]. In
addition, divalent cation and pyrimidine concentration, hydra-
tion levels, and pH vary across the biofilm structure [55], all
factors that may affect antimicrobial efficacy.
3.2. Bacterial cell numbers
Compared to early colonisation, P. aeruginosa cell numbers
are much higher during chronic infection [75], with bacterial
densities of 107 to 108 CFU/g sputum common in chronically
infected patients [76,77]. Such high bacterial cell densities can
degrade or inactivate antibiotics through enzymatic or meta-
bolic activities, potentially reducing antibiotic concentrations in
the airways. For example, P. aeruginosa has been shown to
secrete β-lactamases into the surrounding environment in
membrane bound vesicles, which may become immobilised
within a biofilm matrix [55,78,79] and inactivate antibiotics as
they pass through the biofilm structure [54]. The resulting
decrease in effective antibiotic concentrations in deeper layersotic efficacy in the CF lower airways.
Fig. 2. Potential impacts of novel bacterial species in CF lung infections.
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regulate inducible resistance mechanisms [80]. Bacterial cells
growing in biofilms have also been shown to produce inherently
greater quantities of β-lactamases compared with cells of the
same strain growing planktonically [80].
Another mechanism of biofilm resistance to antibiotics is the
release of planktonic cells under specific conditions, a process
that may be mediated by a range of factors, including the
activity of bacteriophage [81] and nitric oxide concentration
[82]. These actively growing cells may take up and inactivate
antibiotic molecules, resulting potentially in a significant
reduction in the number of antibiotic molecules available to
reach biofilm embedded bacterial cells [54]. It has been
suggested that the periodic release of large numbers of cells
from biofilms in the CF airways may be associated with changes
in clinical symptoms [83]; planktonic “blooms” could poten-
tially respond to exacerbation therapy, while biofilms would
dominate in the interim, reducing the efficacy of maintenance
therapy and influencing the occurrence and resolution of
exacerbations of pulmonary symptoms.
3.3. Genetic and phenotypic diversification of pathogens
The chronic nature of CF lower airway infections, the
heterogeneous airway environment, and the disruption caused
by periodic antimicrobial therapy all favour the genetic
diversification of pathogens into subpopulations. For example,
highly resistant, hypermutable, small colony, virulent and
avirulent variants and clones have been described for a number
of CF pathogens [22,84–86]. Many of the reported adaptations
result in altered metabolic activity [85–88], in turn, leading to
an altered response to antibiotics. Such metabolic changes do
not always appear to result from antibiotic exposure, an
observation that suggests that antibiotic selection is not the
only force behind these adaptive changes. Drug indifference
resulting from a reduced metabolic rate does not however confer
a greater tolerance to classes of antibiotic that kill both rapidly
dividing and slow- or non-growing cells, such as fluoroquino-
lones or metal cations [89,90].
The observation that bacterial populations growing as
biofilms are not eradicated by high concentrations of such
antibiotics [91] is believed to be due, in a significant part, to the
presence of subpopulations of cells that are able survive lethal
concentrations of antibiotics without any specific resistance
mechanisms [91,92]. These sub-populations, known as persister
cells, are not drug-resistant mutants; rather, hyper-resistance in
these persisters is a transient phenotypic change and, on re-
culturing, they revert to mostly wild-type cells with a new sub-
population of persisters [93]. Where persisters exist they are
able to survive antibiotic treatment, re-populating the airway
once antibiotic concentrations have fallen [94]. Persisters occur
both in planktonic and aggregated bacterial populations [96,95]
and their existence is not dependent on identified intercellular
signalling pathway such as quorum sensing [92], suggesting
that persisters inherently comprise a fraction of any bacterial
population [97]. Studies of Escherichia coli have shown that
persister populations may be expanded by antibiotic exposure[98,99] and high levels of persisters are known to occur among
P. aeruginosa populations in the CF airways [100].
In addition to persister cells, the CF airway may contain small
colony variants (SCV). Whilst appearing in both biofilm and
planktonic populations, there is evidence that biofilm formation
may be linked to the development of SCVs [101]. SCVs differ
from the normal phenotype of the populations from which they
originate. For example, S. aureus SCVs are distinguished by their
small colony size, reduced growth rate, pigmentation and
haemolysis, altered expression of virulence factors and auxotro-
phy for haemin, menadione, thiamine or thymidine [87,101–
105]. Further, they are more resistant to the action of aminoglyco-
sides and cell-wall inhibitors, as well as having a tendency to
persist [102,104,105,106]. These variants may represent a stable,
inheritable change or a transient colony type.
Both P. aeruginosa and S. aureus SCVs are known to be
present in CF airway infections [100,107–111], and in addition to
their impact on antibiotic efficacy in vivo, the presence of SCVs is
likely both to lead to an underestimation of bacterial numbers
when determined through culture-based methodologies, and to an
under-representation of such isolates in susceptibility testing.
As described above, in addition to those species traditionally
associated with CF airway disease, a number of studies have
shown that many other bacterial species are also typically
present in the adult CF lung. Many of these are facultative or
obligate anaerobes more commonly associated with the oral
microbiota. The degree to which this wider group of species
contributes directly to airway disease is not yet known,
representing an important area of ongoing research. However,
in addition to any direct role, the presence of this wider group of
species may contribute to disease indirectly, for instance by
increasing the virulence of key pathogens such as P. aeruginosa
[112], or by “consuming” administered antibiotics and thus
diluting their effects on the intended population (usually
P. aeruginosa) (Fig. 2). As such, this wider bacterial community
may represent a potential target for therapy.
Box 2
Current outcome measures. Categories reflect the use of these
outcomes measures in a number of previous studies ([36,115,128–
130,142,160], and reviewed in [12]).
Short-term outcomes
Primary measures
• Lung function (absolute change or percentage change
compared to baseline)
• Resolution of clinical signs and symptoms
• Changes in sputum bacteriology (quantitative or qualitative)
• Adverse effects (e.g. allergic reactions, candidal infections)
Secondary measures
• Quality of life
• Change in nutritional status (weight, height, BMI)
• Time to exacerbation
• Change in inflammatory status (blood or sputum markers)
• Cost




• Frequency of exacerbations
• Lung function (absolute change or percentage change
compared to baseline)
• Development of antibiotic resistant strains
Secondary measures
• Adverse effects (decline in renal function)
• Number of courses of IV antibiotics
• Quality of life
• Cost
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Despite these barriers to effective action, antibiotic treatment
is associated with a decrease in bacterial load and improvement
in symptoms when given for the treatment of CF respiratory
exacerbations [28,113–115]. Although eradication is rarely
achieved, many trials have reported a decrease in bacterial
numbers of one to two log10 orders. What are the reasons for
this efficacy, albeit limited, given the factors described above?
Physical barriers such as mucins or DNA may be saturable,
and sufficient antimicrobial molecules may then reach bacterial
cells, with the degree to which the extracellular matrices
associated with biofilms restrict the penetration of antimicrobial
agents differing significantly between antibiotics [116–120].
Furthermore, as above, antibiotics may selectively kill a
planktonic subpopulation of cells, while sparing many of the
co-infecting biofilm-dwelling cells [83]; if these planktonic
cells are major contributors to the signs and symptoms of
exacerbations, this antibiotic effect could be sufficient to speed
recovery.
Whilst targeting specific routinely-cultured pathogens (such as
P. aeruginosa) antibiotics may also impact other bacteria in the
CF lung, resulting in a decreased total bacterial burden. For
example, using standard, selective cultures, anti-pseudomonal
antibiotics have been shown to have more significant antimicro-
bial effects in vivo on H. influenzae [27] than on P. aeruginosa,
raising the question of whether anti-pseudomonal antibiotics
ameliorate exacerbations through their targeted species, or
through another mechanism. Similarly, antibiotics such as
azithromycin are likely to have an impact on the bacterial
community present in the CF airways in ways not yet well
defined. This possibility may be reflected by the finding that
azithromycin reduces exacerbations in people culture-negative
for P. aeruginosa [36].
Finally, antibiotics may impact host cells directly, for
example by decreasing inflammation, in turn, resulting in an
increase of lung function. For instance, azithromycin is known
to have a wide range of anti-inflammatory effects ([121] and
others — reviewed by [122]) that may influence clinical signs.
In addition, azithromycin is known to aid sputum expectoration,
prevent airway remodelling, limit tissue damage, and correct
airways surface liquid composition ([123–127], reviewed by
[122]). The multiple non-antibiotic effects of azithromycin may
explain why administration of this drug is associated with
positive outcomes, including improvement in lung function and
in the frequency of episodes of infective exacerbation, despite
the lack of any observed, significant changes in bacterial
densities [128–130]. At sub-inhibitory concentrations, a
number of macrolide antibiotics, including azithromycin, can
influence the gene expression of P. aeruginosa ([131–133] and
others), and interfere with quorum sensing [134,135]. Disrup-
tion of quorum sensing pathways in turn affects the ability of
P. aeruginosa to express a range of virulence traits, including
the formation of biofilms [136].
Guidelines governing antibiotic selection in CF care have
historically supported the use of in vitro sensitivity testing to
inform antibiotic selection [137,138]. However, the usefulnessof such analysis is now being questioned [139]. This is
primarily due to the observation of wide variability in the results
of susceptibility testing of multiple isolates of P. aeruginosa
from individual sputum samples by more than one laboratory or
technician [140]. Foweraker et al. reported substantial differ-
ences in antibiotic sensitivities between isolates with the same
colony morphology [86], as well as differences in results from
the same isolates among different observers [140]. Further,
these problems do not appear to be resolved by the ongoing
refinement of the way in which such analysis is performed
[140–141]. Given these findings, the poor correlation between
in vitro susceptibility data and clinical outcome is unsurprising
[142,143].
It must also be considered that antibiotics are usually given
as part of a complex, multimodal regimen, that includes
mucolytic drugs, physiotherapy, and nutritional supplements,
all of which may affect the same clinical outcome measures and
patient reported outcomes used to determine antibiotic efficacy
(Box 2). Further, in a proportion of cases, the decline in
respiratory health that precipitates acute antibiotic therapy
might result from a non-bacterial trigger, such as respiratory
viral infection [144–146]. In such cases, the role of antibiotics
in recovery is difficult to predict.
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case, being an antibiotic most often given for its theoretical non-
antibiotic impact. However, these same issues of indirect or
poorly defined therapeutic impact affecting conventional
outcome measures will exist to some degree for all antibiotics.
Taken together, a range of factors are likely to contribute to the
effect of an administered antibiotic on lung function in
chronically infected CF patients. As such, determing the
individual contribution of antibiotics to clinical improvement,
and the mechanism of any such effect, is very difficult.
4. Is antibiotic therapy doing more harm than good in CF
patients?
Typically, treatment strategies are designed to achieve as high
a concentration of antibiotics at the site of infection as possible,
with appropriate upper limits determined primarily by toxicolog-
ical and pharmacokinetic considerations. With continuing in-
creases in patient longevity, and the concomitant rise in the total
number of courses of antibiotics recieved, there is growing
concern about cumulative damage, particularly to renal and otic
function, that can result from such drug exposure [148–151].
Furthermore, antibiotic resistance rates are known to increase
with multiple cycles of therapy [27], yielding multi-resistant
clones which have been associated with both worse outcomes
[152], and with epidemic infection among CF patients [153,154].
Increases in lung function observed in CF antibiotic treatment
trials tend to decrease when repeated. For example, while in the
1999 tobramycin trial [155] an increase of FEV1 of more than
10% was observed, such increases are currently rarely seen with
this drug [156]. Furthermore, bacteria that survive antibiotic
treatment may adapt phenotypically by becoming even more
resistant to killing, such as by antibiotic-mediated up-regulation
of cyclic-di-GMP levels byP. aeruginosa [157] and an increase in
alginate synthesis [48,79].
On the other hand, there is evidence of an overall beneficial
effect of antibiotics on long-term respiratory outcomes in CF:
lung function declines less rapidly with chronic suppressive
therapy, as does the frequency of acute exacerbations and
inflammation [128–130,149,158–161].
5. Novel strategies to rationalise antibiotic therapy in
CF patients
There are many factors that must be considered in the design
of any antibiotic treatment strategy. These include, but are not
limited to, the drug or drug combination used, formulation,
mode of delivery, frequency of delivery, dose, the need for
allergic desensitisation, duration of treatment, potential side-
effects, potential antibiotic synergy, the use of non-antibiotic
co-therapies, and inter-treatment interval. Given the complexity
of CF respiratory infections, making decisions based on our
current microbiological understanding strays close to guess-
work. Indeed, it could be argued that there is insufficient
evidence to support any tailoring of antibiotic treatment based
on current bacterial surveillance strategies in individual CF
patients, as opposed to empirically chosen antibiotics. Never-theless, our expanding understanding of CF microbiology offers
new opportunities to rationally design and test novel treatment
strategies based on the best current data.
5.1. Characterization of microbial pathogens
Currently, CF antibiotic therapies are usually informed by
two types of microbiological data: the semi-quantitative,
selective culture-based detection of the defined group of
pathogens set out above, and the determination of their
antibiotic susceptibility profiles in vitro [139]. The detection
of pathogens through culture-based microbiology provides a
reasonably robust indication of the presence of a limited group
of key pathogens. However, the presence of bacteria in forms
that grow poorly in vitro, such as small colony variants and
auxotrophic strains [162–166], can lead both to false negative
results and inaccuracy in enumeration. Further, there is
increasing recognition that species refractory to culture under
standard diagnostic conditions may be clinically significant
[21,33,109]. As such, in order to obtain a more substantial basis
for the design of drug trials or treatment strategies, it is
necessary to compile a body of empirical data, based on direct
microbiological measurements that accurately represent in vivo
scenarios.
Bacteria in CF airways could influence the progression of lung
disease in at least two ways: They could have a passive impact,
through the host detecting their presence and an immune response
being triggered, or they could have an active impact, through the
expression of genes that code for proteins involved in
pathogenicity. Following this logic, the key questions in
describing the success of antimicrobial therapy could be:
1) Has there been a reduction in viable bacterial load, either for
total bacteria or for specific species?
2) Has there been a change in the expression of genes
associated with pathogenicity?
5.1.1. Identifying changes in viable bacterial load
Due to diversity of growth phenotypes of bacteria isolated
from CF airways (as described above), traditional culture-based
microbiology is unable to provide sufficiently representative
data when applied to bacterial enumeration in CF respiratory
samples. However, culture-independent approaches to bacterial
enumeration can avoid many of the problems associated with
culture-based strategies. Nucleic acids can be extracted directly
from clinical samples and quantitative PCR (Q-PCR) used to
enumerate either total bacteria or bacteria belonging to a
particular species of interest that are present. Further, nucleic
acid extraction and Q-PCR can be, to a large degree, automated,
with each extract being used for multiple species-specific
assays, thus reducing associated costs.
However, whilst such culture-independent strategies have the
advantage of not requiring in vitro cultivation to be performed,
this is also one of their key flaws. Standard PCR-based
diagnostics are unable to differentiate between DNA present in
viable bacterial cells, in non-viable cells, and in the extracellular
matrix. A failure to exclude non-viable bacteria from analysis is
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given that DNA may persist in the CF airways for extended
periods of time without being cleared or degraded [167–169].
The contribution of DNA other than that present in viable
bacteria can be effectively excluded by pre-treating samples with
propidium monoazide photo-crosslinking. Whilst a relatively
simple additional step, this method has been shown to be effective
in preventing DNA from non-viable bacterial cells present in CF
sputum from acting as PCR template [170]. The use of Q-PCR, in
combination with PMA treatment, has been used to show a
decrease in density of P. aeruginosa in CF sputum samples as a
result of IV antibiotic therapy [171].Whilst such a reduction is not
evident in all patients, and comparison with results from standard,
culture-based studies (in the absence of a gold standard measure
of microbial content) will be required before they can be
employed diagnostically, such a strategy may allow accurate
enumeration of bacteria in CF respiratory samples through the
addition of a relatively minor step in sample processing.
5.1.2. Identifying changes in pathogen behaviour
The expression of particular behavioural traits by CF
pathogens is likely to contribute to lung disease pathogenesis
[172,173]. Treatments that are able tomodify pathogen behaviour
so that virulence traits are not exhibited may therefore be
beneficial, even where the number of bacteria present remains
unaltered.
In many cases, such changes in behaviour will be reflected in
gene and protein expression patterns. A meta-transcriptomic or
-proteomic analysis could therefore be used to identify genes or
molecules whose up- or down-regulation correlates with clinical
symptoms, with such data used to inform the development of
biomarkers and outcomes measures [174].
Analysis based on gene expression or protein production
each have both advantages and disadvantages. The ability of
protein-based analysis to report short-term changes is likely to
be reduced by poor clearance of material from the CF lower
airways [167–179] and low rates of protein turnover. Further,
potential biomarker proteins may be of very low abundance
within the meta-proteome, making their initial identification
through global profiling techniques difficult. However, once
useful protein biomarkers have been identified, routine
quantification can be performed through relatively simply
immuno-assays.
In comparison to protein, mRNA has a very short half-life,
making transcriptomic analysis better suited for characterising
rapid changes that occur as a result of acute therapy. Broad meta-
transcriptomic analysis can be achieved through the reverse
transcription of total mRNA extracts and their subsequent
characterisation, either by microarray analysis or through high
throughput next generation sequencing. Again, identification of
genes whose transcription correlates with clinical data through
such a process would allow specific assays to be developed. The
relative instability of mRNA presents a significant challenge in
the search for biomarkers, with the recovery of sufficient high
integrity mRNA from clinical samples a key issue. Some
technological advance is therefore likely to be required before
such an approach can be applied to the large patients groups andtemporal sample sets needed to identify useful biomarkers.
Further, with deployment of such technology in a diagnostic
setting currently a distant proposition.
Novel protein or mRNA biomarkers may be most useful as
predictors of exacerbations, and/or to provide an indication for
treatment. For example, the identification of a bacterial gene or
protein whose upregulation precedes the worsening of pulmo-
nary symptoms could provide a cue to initiate IV antibiotic
therapy before clinical signs and symptoms become apparent.
However, to limit the use of such insight to an indication for
the initiation of treatment might be a missed opportunity. Whilst
bactericidal treatments ultimately prevent gene expression of
bacterial cells, such approaches are associated with a number of
significant drawbacks due to the high concentrations of antibiotics
often required. Since sub-inhibitory antibiotics have been shown
tomodify bacterial gene expression in ways that are likely to have
clinical significance [132,157], the potential for bacterial markers
to be used to re-design antimicrobial therapy for CF airway
infections (for example, to study the effects of less toxic drugs
and/or doses in clinically meaningful ways) should not be
ignored. The rationale for antibiotic therapy, both in the
management of chronic infection and in the treatment of acute
periods of exacerbation, could be shifted from achieving a
reduction in the bacterial load in the airways (an outcome that has
not been definitively related with clinical improvement [27]), to a
reduction of the expression of genes associated with poor clinical
outcomes, or the up-regulation of genes associated with clinical
stabilty. For example, recent data suggest that the production of
pyocyanin byP. aeruginosa cells can cause significant changes in
gene expression profiles of bronchiolar epithelial cells [173]. If
these epithelial expression changes can be correlated with clinical
outcomes, intervening to prevent the production of pyocyanin
may confer clinical benefits. The use of antibiotics as “behaviour
modifers” in this way has been demonstrated in the treatment of
methicillin resistant S. aureus (MRSA), where protein synthesis
inhibitory antibiotics such as aminoglycosides and macrolides
can be used to inhibit exotoxin production [175]. Such strategies
are potentially applicable more widely.
5.2. Selection of antibiotics for the treatment of lung infections
in CF patients
As described above, evidence indicates that the traditional
strategy of using susceptibilities to guide antibiotic selection for
CF treatment is of limited value [143]. As a result of this lack of
informative data, antibiotics are frequently chosen for the
treatment of bacterial lung infections based on factors such as
whether they have worked well for a given patient previously,
their cost, availability, or toxicity. A reduction in pulmonary
symptoms is the primary aim of therapy in this context, and as
such, should be the ultimate measure of success. However, failing
to achieve a better understanding of the direct impact of
antibiotics on their target – populations of bacterial pathogens
in the airways – confounds a better understanding of when, why,
and how antibiotics result in clinical outcomes, precluding
improvement of current therapeutic strategies. Thus, a better
understanding of the overall impact of antibiotics on CF
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outcomes, is needed.5.3. Treatment of acute exacerbations in CF
The antibiotic strategy most commonly used for acute CF
pulmonary exacerbations is similar to that used to eradicate
bacteria in acute infection contexts elsewhere, typically involving
a ten to fourteen day course of IV antibiotics [5,11]. This is despite
the wide acceptance that eradication of chronically infecting
pathogens is not a realistic aim in the majority of cases [176].
Whilst the ‘14 day’ schedule is an historically accepted approach,
supported by the weight of clinical experience [177], there is little
evidence to indicate whether this is the most appropriate format.
For example, there is yet to even be a sufficiently powered
comparison of IV antibiotic benefit versus placebo [5]. Whilst
retrospective analysis of FEV1 response to IV antibiotic therapy
data in the CFF Patient Registry suggests that treatment periods of
1–2 weeks are associated with better lung function outcomes
compared with shorter or longer treatment periods [178], the fact
that patients treated for longer periods do worse is difficult to
explain from amicrobiological standpoint (and could conceivably
be attributable to confounding — patients who are sicker may
often be treated for longer, rather than the reverse). Further, if an
inability to achieve eradication is accepted, there is no consensus
rationale for dose determination from a microbiological perspec-
tive. In the absence of compelling evidence about the effective-
ness of the 14 day duration of therapy, such high dose strategies
for acute exacerbations persist. The generation of detailed
microbiological data, in parallel with clinical trials using standard
clinical outcome measures, would therefore provide a comple-
mentary basis for assessing novel strategies empirically.5.4. Regulatory aspects of antibiotic therapy in CF patients
Current systems for determining antibiotic efficacy, such as
those employed by the Food and Drug Administration (FDA)
[179], rightly rely on validated clinical outcomes. FDA guidelines
on the development of antimicrobials for respiratory infections
state “Although microbiological outcome may provide useful
information regarding the biological activity of antimicrobials,
microbiological outcome is not a direct measure of benefit to
patients and, therefore, should be viewed as being supportive
information but not as a substitute for clinical outcome in a
specific trial” [180].
Whilst sophisticated bacteriological measures cannot be
applied in such a role until they have been further validated and
applied to large patient groups and longitudinal sample sets,
antibiotic treatment studies offer an excellent opportunity to do
this. Despite not directly contributing to drug licencing, the
widespread application of such measures during drug trials
would result in the generation of large and detailed data sets, in
turn providing a potential basis for the more formal inclusion of
such assays as routine outcome measures (the inclusion of such
secondary and additional endpoints is broadly supported by
FDA guidelines, where sufficiently powered [180]). Further, thedata generated would be invaluable in helping us determine the
microbial determinants of CF lung disease.5.5. Unanswered questions regarding antibiotic treatment in CF
Despite a rich literature, with respect to antibiotic choices
and delivery modes, many more specific questions remain. For
example, does dry powder inhalation result in altered drug
distribution in vivo compared to nebulization? Do liposomal
drug formulations result in better biofilm penetration? Do
inhaled antibiotics differ from IV and oral therapies in the
persistence time within the lung compartment? Is combination
therapy more effective than monotherapy in killing target
organisms or other microbes? What are the effects of
antimicrobial drugs on inflammation? Is tailored or empirical
treatment more effective? Does cycling different maintenance
treatments offer advantages over single-agent maintenance?
Should IV treatments be administered prophylactically, or only
as indicated by clinical or laboratory parameters? These and
many more questions remain to be answered, and until they are,
guidelines will be difficult to compose and defend, and
therapeutic strategies are likely to continue to differ between
treatment sites.6. Antibiotic therapy beyond CF
In many ways, CF lung disease represents a model system,
providing insight into the mechanisms involved in, and potential
treatments for, a wide range of acute and chronic infections.
Techniques and concepts developed through the study of CF
respiratory infections can help develop our understanding of an
array of other respiratory infections, including those associated
withCOPD, non-CF bronchiectasis, chronic intubation, aswell as
chronic, polymicrobial infections more widely.7. Summary
Sincewidespread antibiotic therapy for CF lung infectionswas
introduced in the 1960s, it has developed into a central component
of care. A process of refinement of antibiotic strategy, including
progress in the drugs available, and the manner in which they are
delivered, has resulted in a significant beneficial impact on the
course of CF airway disease. However, as antibiotic resistance
develops in step with drug development, and the cumulative
levels of antibiotics recieved by patients increases with improving
life expectancy, the need to develop more effective treatment
strategies is as urgent as ever. The inclusion of sophisticated
bacteriology in development and assessment of antibiotic
treatment strategies is a vital next step in the process of improving
the effectiveness of CF antibiotic therapy.Acknowledgment
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